See Shionogi-Sponsored Publications
Publications
Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.
Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis
Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019)
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019)
In vitro activity of cefiderocol against meropenem-nonsusceptible Gram-negative bacilli with defined β-lactamase carriage: SIDERO-WT surveillance studies, 2014-2019
In vitro activity of cefiderocol against meropenem-nonsusceptible Gram-negative bacilli with defined β-lactamase carriage: SIDERO-WT surveillance studies, 2014-2019
A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part
A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part
A randomized phase 2/3 study of ensitrelvir, a novel Oral SARS-CoV-2 3C-like protease Inhibitor, in Japanese patients With mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part
A randomized phase 2/3 study of ensitrelvir, a novel Oral SARS-CoV-2 3C-like protease Inhibitor, in Japanese patients With mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part